Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Balancing Risk Post-PCI

Published: 13 October 2022

  • Views:

    Views Icon 13785
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.

 

The third broadcast in this series, focused on Balancing Risk Post-PCI. In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.

 

Prof Roxana Mehran (Mount Sinai Hospital, New York, US) chairs the proceedings, and is joined by Prof Dominick Angiolillo (University of Florida College of Medicine-Jacksonville, US), Prof Marco Valgimigli (Instituto Cardiocentro Ticino, Lugano, CH) and Prof Pascal Vranckx (University of Hasselt, BE) for a series of insightful presentations and discussions.

 

Register now for the final broadcast in this series, on Stroke Prevention, live on Monday 13 February 2023.

 

You can also catch up on previous broadcasts in this series which reviewed Acute Coronary Syndrome and Chronic Coronary Syndrome.

 

This broadcast series is supported by an unrestricted educational grant from AstraZeneca.

Key Learning Objectives

Following the completion of this programme, physicians will be in a position to:

  • Apply the use of validated bleeding risk tools across a wide range of patients
  • Use guidelines and clinical judgement to select antiplatelet therapy regimens in patients at elevated bleeding risk
  • Recall the clinical significance of trial data assessing truncated periods of DAPT
  • Prescribe confidently in patients judged to be at elevated bleeding risk
  • Recall the safety profiles of different P2Y12 inhibitors

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • Nurses and any other allied HCPs

More from this programme

Part 1

Clinical Vignette and Panel Discussion

Prof Marco Valgimigli opens this broadcast on balancing bleeding and ischaemic risk post percutaneous coronary intervention, by presenting a high-risk case.

Part 2

Assessing Bleeding Risk Post-PCI

Prof Roxana Mehran discusses optimal strategies for calculating and weighing-up bleeding and ischaemic risk post-PCI, then applies this to our case study which was presented in part one.

Part 3

Optimum Duration of DAPT: Overview of Current Data

Prof Dominick Angiolillo reviews current guidance and evolving clinical data to highlight different antithrombotic strategies to reduce bleeding risk, including shortening dual anti-platelet and single anti-platelet approaches.

Part 4

Bleeding Risk Mitigation - Safety in Clinical Practice and Panel Discussion

Prof Pascal Vranckx explores patient-tailored anti-thrombotic options for subgroups within high bleeding risk and high ischaemic risk patients, tying this in with a forthcoming network meta-analysis and European consensus statement. The panel then bring the discussion back to the case presented at the start, and have an interactive discussion, answering questions from the audience.

Faculty Biographies

Pascal Vranckx

Pascal Vranckx

Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services

Prof Pascal Vranckx is a Clinical Consultant in Interventional Cardiology and Medical Director of Cardiac Critical Care Services at the Hartcentrum Hasselt in Belgium, and Professor of Medicine at the University of Hasselt, Belgium.

Prof Vranckx is also board member of the European Cardiovascular Research Institute, in Rotterdam, The Netherlands. 

View full profile